Echosens Highlights New EASL Clinical Practice Guidelines: Unprecedented Recommendation for Non-Invasive FibroScan and Care Management
Echosens , a high-technology company offering the FibroScan® family of products, announces the release of new guidelines from the European Association for the Study of the Liver (EASL), a professional association for individuals researching liver disease. These guidelines represent a significant advance for the non-invasive management of patients with liver diseases and an unprecedented level of recommendation for Echosens’ solutions.
“We’re very pleased that these new guidelines are very prescriptive for FibroScan parameters, positioning our technologies as the cornerstone of non-invasive tests (NIT) for the future of liver disease management—across the liver care continuum and all population groups,” says Dominique Legros, Group CEO, Echosens. “As the NIT of reference, FibroScan combines standardization, clinical performance and accessibility for early patient identification, in first-line after Fib-4, either in primary care, diabetology clinic or liver clinic, and for advanced liver disease patient management, portal hypertension and hepatocellular carcinoma (HCC) risk stratification.”
EASL guidelines highlights include:
- Liver stiffness measurement (LSM ) by transient elastography (TE ) received support from 13 “strong recommendations” and four other recommendations or supportive statements.
- Controlled attenuation parameter (CAP) is now mentioned in the guidelines, with clear cut-off for steatosis diagnosis.
- Spleen stiffness measurement (SSM) is now recommended as an additional NIT to further improve risk stratification and refine the risk of high-risk varices.
Across all population groups, FibroScan was mentioned in 18 recommendations or statements, including in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), hepatitis C virus, including post sustained virologic response (PSVR), primary biliary cirrhosis (PBC)/primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH), as well as in at-risk populations, such as patients with metabolic risk factors and/or harmful use of alcohol. All recommended cut-off values are clearly specified for LSM by TE.
Jon Gingrich, CEO, Echosens North America, says, “We’re highly gratified by these new guidelines, which further demonstrate the value of FibroScan for comprehensive management of liver health in the battle against a global liver disease epidemic. EASL is a key facilitator of excellence in liver research and liver-related innovation.”
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 2,500 peer reviewed publications and 70 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOODY’S-ESG3.8.2021 10:16:06 CEST | Press release
Moody’s ESG Solutions Launches Solution to Help Investors Assess Alignment With UN Global Compact
BOEHRINGER-INGELHEIM3.8.2021 10:02:05 CEST | Press release
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
SES-NETWORKS/ORANGE3.8.2021 08:52:03 CEST | Press release
SES Networks Expands Partnership With Orange to Enhance Maritime Services
GOPHER-INVESTMENTS3.8.2021 08:02:12 CEST | Press release
Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer
RELIEF3.8.2021 07:05:13 CEST | Press release
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis
P.I.-WORKS3.8.2021 07:02:06 CEST | Press release
Smart Engages P.I. Works for Expanded Network Automation Solution
CA-PERSONALIS2.8.2021 22:07:05 CEST | Press release
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom